

Corporate Action Notice

September 21, 2012

Reverse Split

Name: Powerchip Technology

DR 144A CUSIP: 73931M748

DR ISIN: US73931M7487

DR RegS CUSIP: 73931M730

DR ISIN: US73931M7305

Ratio (DRs:Underlying Shares): 1:10

BNY Mellon has been advised that Powerchip Technology announced a capital reduction in the local market at a rate of 400 new shares per 1,000 shares held. As a result, BNY Mellon will affect a reverse split on the ADRs at a rate of 4 new DRs for every 10 DRs held (0.4 DRs for every 1 DR held).

Effective September 28, 2012, DR holders of Powerchip Technology are required on a mandatory basis to surrender their DRs for cancellation and exchange ten (10) "OLD" DRs (144A CUSIP# 73931M748 & RegS CUSIP# 73931M730) for four (4) "NEW" DRs (144A CUSIP# 73931M722 & RegS CUSIP# 73931M714). Only whole DRs will be distributed. **DR holders will be charged a cancellation fee of \$0.05 for each DR surrendered.**

The following are the trading particulars:

	<u>OLD</u>	<u>NEW</u>
144A CUSIP #:	73931M748/US73931M7487	73931M722/US73931M7222
RegS CUSIP #:	73931M730/US73931M7305	73931M714/US73931M7149

The existing ratio of one (1) American Depositary Share, representing ten (10) ordinary shares remains the same. BNYM will attempt to sell any fractional DRs and distribute the cash proceeds.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

<i>New York</i>	<i>London</i>	<i>Hong Kong</i>
Ravi Davis	Damon Rowan	Joe Oakenfold
Vice President	Vice President	Vice President
+1 212 815-4245	+44 207 964 6527	+852 2 840 9717
Ravi.davis@bnymellon.com	damon.rowan@bnymellon.com	joe.oakenfold@bnymellon.com

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.